Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q3
$1.26M Sell
4,685
-50
-1% -$12.5K 1.15% 27
2023
Q2
$1.05M Sell
4,735
-230
-5% -$53.4K 0.92% 33
2023
Q1
$1.2M Sell
4,965
-230
-4% -$56.5K 1.07% 29
2022
Q4
$1.36M Sell
5,195
-30
-0.6% -$8.04K 1.21% 27
2022
Q3
$1.18M Hold
5,225
1.12% 29
2022
Q2
$1.26M Hold
5,225
1% 29
2022
Q1
$1.26M Hold
5,225
1% 29
2021
Q4
$1.18M Buy
+5,225
New +$1.1M 0.86% 35

Other funds holding AMGN

Kenfarb & Co's AMGN Position: Q3 2023 in Review

Kenfarb & Co reduced its Amgen (AMGN) stake by 1.1% in Q3 2023, selling an estimated $12.5K and leaving 4,685 shares worth $1.26M. The position accounts for 1.15% of the portfolio, ranked #27.

Kenfarb & Co first reported a position in AMGN in Q4 2021 and has held it in 8 quarters since. The position peaked at $1.36M in Q4 2022. 2,501 funds tracked by Wall St. Rank hold AMGN as of Q3 2023.

  • Kenfarb & Co held 4,685 shares of Amgen worth $1.26M as of Q3 2023.
  • Kenfarb & Co sold 50 Amgen shares in Q3 2023, an estimated $12.5K.
  • Amgen made up 1.15% of Kenfarb & Co's portfolio in Q3 2023, its #27 holding.
  • Kenfarb & Co first reported a position in Amgen in Q4 2021 and has held it in 8 quarters since.
  • Kenfarb & Co's Amgen position peaked at $1.36M in Q4 2022.
  • 2,501 funds tracked by Wall St. Rank held Amgen as of Q3 2023.

Based on Kenfarb & Co's 13F filing for Q3 2023, filed 14 Nov 2023.